concept

P-TAU217

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about P-TAU217: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

33Connections

20Hypotheses

1Analyses

23Outgoing

10Incoming

0Experiments

2Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	P-TAU217
Related Diseases	Alzheimer's disease

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

p-tau-217

biomarker · 4980 words

→

Pathway Diagram

graph TD
    P_TAU217["P-TAU217"]
    P_TAU217 -->|"correlates_with"| neurodegeneration["neurodegeneration"]
    P_TAU217 -.biomarker for.-> A__pathology["Abeta pathology"]
    P_TAU217 -->|"correlates_with"| Brain_Atrophy["Brain Atrophy"]
    P_TAU217 -->|"correlates_with"| Cognitive_Impairment["Cognitive Impairment"]
    P_TAU217 -.biomarker for.-> Neurodegeneration["Neurodegeneration"]
    P_TAU217 -.biomarker for.-> Alzheimer_Disease["Alzheimer Disease"]
    P_TAU217 -.biomarker for.-> Alzheimer_s_Disease["Alzheimer's Disease"]
    P_TAU217 -.biomarker for.-> amyloid_beta_pathology["amyloid-beta pathology"]
    mAb2A7["mAb2A7"] -->|"targets"| P_TAU217
    Mab2A7["Mab2A7"] -->|"targets"| P_TAU217
    Tau_Positivity["Tau Positivity"] -->|"correlates_with"| P_TAU217
    Amyloid_Beta_Positivity["Amyloid Beta Positivity"] -->|"correlates_with"| P_TAU217
    APOE["APOE"] -->|"modulates"| P_TAU217

Outgoing (23)

Target	Relation	Type	Str
h-2901c57778	targeted_by	hypothesis	1.00
neurodegeneration	correlates_with	process	1.00
Neurodegeneration	biomarker_for	process	0.95
Cognitive Status	biomarker_for	phenotype	0.95
Aβ pathology	biomarker_for	phenotype	0.95
Alzheimer Disease	biomarker_for	disease	0.95
Brain Atrophy	correlates_with	phenotype	0.95
Cognitive Impairment	correlates_with	phenotype	0.95
Alzheimer's Disease	biomarker_for	disease	0.93
amyloid-beta pathology	biomarker_for	process	0.93
Amyloid Beta Pathology	biomarker_for	phenotype	0.93
Tau Pathology	biomarker_for	phenotype	0.93
Brain Atrophy	correlates_with	phenotype	0.90
Cognitive Impairment	correlates_with	phenotype	0.90
Csf Biomarkers	correlates_with	biomarker	0.88
Apoptosis	involved_in	process	0.85
Alzheimer's disease	biomarker_for	disease	0.80
ALZHEIMER	biomarker_for	disease	0.80
Amyloid PET positivity	predicts	phenotype	0.70
cognitive impairment	associated_with	process	0.70
synaptic functions	regulates	pathway	0.70
Preclinical symptoms	predicts	phenotype	0.70
brain atrophy	associated_with	process	0.70

Incoming (10)

Source	Relation	Type	Str
h-2901c57778	targets	hypothesis	1.00
mAb2A7	targets	drug	0.98
Mab2A7	targets	drug	0.95
Tau Positivity	correlates_with	phenotype	0.92
Amyloid Beta Positivity	correlates_with	phenotype	0.90
obicetrapib	suppresses	drug	0.88
Cardiovascular Risk	modulates	phenotype	0.85
APOE	modulates	gene	0.75
mAb2A7	inhibits	drug	0.70
Amyloid PET	correlates_with	biomarker	0.70

Targeting Hypotheses (20)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Temporal Decoupling of CSF p-tau217 Normalization from Amylo	0.595	neurodegeneration	-
CSF p-tau217 Normalization Reflects Amyloid-Driven Tau Patho	0.586	neurodegeneration	-
Residual Vascular Amyloid Prevents Complete CSF p-tau217 Nor	0.585	-	Can CSF p-tau217 normalization serve as
CSF p-tau217 Normalization Occurs Earlier Than Amyloid PET N	0.565	-	Can CSF p-tau217 normalization serve as
Gamma-Entrained PV Interneuron Networks Enable Precision p-t	0.550	molecular neurobiology	View

Gamma-Entrained PV Interneurons Enable p-tau217-Guided Preci	0.547	molecular neurobiology	View
Combined p-tau217 + p-tau231 Panel Increases Specificity for	0.546	neurodegeneration	-
Cerebrospinal Fluid p-tau217-Guided Astrocyte-Derived Extrac	0.542	molecular neurobiology	View
Microglial Reactivation Status Modifies Amyloid Clearance an	0.524	neurodegeneration	-
CSF p-tau217 Normalization Requires Intact Synaptic Function	0.515	neurodegeneration	-
CSF p-tau217 Threshold of <0.15 pg/mL Predicts Durable Clini	0.512	neurodegeneration	-
Neurogranulin Predicts p-tau217 Reliability by Identifying P	0.498	neurodegeneration	-
Amyloid Plaque Clearance Triggers Downstream Reduction in Ta	0.475	-	Can CSF p-tau217 normalization serve as
Gamma-Entrained PV Interneurons Enable Precision p-tau217-Gu	0.464	molecular neurobiology	View
Gamma-Entrained P-tau217 Biomarker Cascades Optimize lncRNA-	0.431	molecular neurobiology	View
Neurogranin Co-Normalization Validates p-tau217 as a Surroga	0.415	-	Can CSF p-tau217 normalization serve as
Axonal Integrity Recovery Following Amyloid Clearance Drives	0.365	-	Can CSF p-tau217 normalization serve as
Individual Baseline Variability in p-tau217 Half-Life Dictat	0.335	-	Can CSF p-tau217 normalization serve as
Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-00	0.323	molecular neurobiology	View
P-tau217 Isoform Shift Indicates Mechanistic Transition Poin	0.245	-	Can CSF p-tau217 normalization serve as

Mentioning Analyses (1)

Scientific analyses that reference this entity

Multi-modal Biomarker Panel Design for Early AD Detection

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.559

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (2)

Multi-agent debates referencing this entity

Can a multi-modal biomarker panel combining plasma proteins, neuroimaging featur

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

Should clinical practice adopt multi-modal biomarker panels now, or wait for sin

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

Related Research

Hypotheses and analyses mentioning P-TAU217 in their description or question text

Gamma-Entrained PV Interneurons Enable p-tau217-Guided Precision Dosing of lncRN

Score: 0.547 · molecular neurobiology · 2026-04-17

## Mechanistic Overview Gamma-Entrained PV Interneurons Enable p-tau217-Guided Precision Dosing of lncRNA Therapeutics i

Cerebrospinal Fluid p-tau217-Guided Astrocyte-Derived Extracellular Vesicle Deli

Score: 0.542 · molecular neurobiology · 2026-04-17

## Mechanistic Overview Cerebrospinal Fluid p-tau217-Guided Astrocyte-Derived Extracellular Vesicle Delivery of lncRNA-0

Amyloid Plaque Clearance Triggers Downstream Reduction in Tau Kinase Activity, N

Score: 0.475 · unknown disease · 2026-04-26

Donanemab-mediated amyloid plaque clearance reduces microglial activation and neuronal injury, which diminishes the path

Gamma-Entrained PV Interneurons Enable Precision p-tau217-Guided lncRNA Exosome

Score: 0.464 · molecular neurobiology · 2026-04-21

## Mechanistic Overview Gamma-Entrained PV Interneurons Enable Precision p-tau217-Guided lncRNA Exosome Therapy in Early

Gamma-Entrained P-tau217 Biomarker Cascades Optimize lncRNA-9969 Exosome Therapy

Score: 0.431 · molecular neurobiology · 2026-04-21

## Mechanistic Overview Gamma-Entrained P-tau217 Biomarker Cascades Optimize lncRNA-9969 Exosome Therapy Precision in Ea

Neurogranin Co-Normalization Validates p-tau217 as a Surrogate for Synaptic Heal

Score: 0.415 · unknown disease · 2026-04-26

CSF p-tau217 normalization must co-occur with neurogranin (Ng) stabilization to confirm cessation thresholds. Ng reflect

Axonal Integrity Recovery Following Amyloid Clearance Drives CSF p-tau217 Normal

Score: 0.365 · unknown disease · 2026-04-26

Donanemab treatment reduces amyloid-induced axonal transport deficits and endosomal trafficking impairment. Restored axo

Individual Baseline Variability in p-tau217 Half-Life Dictates Cessation Thresho

Score: 0.335 · unknown disease · 2026-04-26

CSF p-tau217 levels reflect a dynamic equilibrium between neuronal tau release and CSF clearance, with significant inter

Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Windo

Score: 0.323 · molecular neurobiology · 2026-04-17

## Mechanistic Overview Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window in AD starts f

P-tau217 Isoform Shift Indicates Mechanistic Transition Point for Cessation Elig

Score: 0.245 · unknown disease · 2026-04-26

Donanemab treatment causes a shift from disease-specific p-tau217 (produced via amyloid-driven kinase activation) toward